Summit Therapeutics SMMT Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $619.03M+15.1% | $537.67M+21.7% | $441.76M+26.8% | $348.39M+104% | $171.17M+13.5% | ||
| $603.76M+8.4% | $556.75M+12.9% | $493.35M+20.1% | $410.89M+539% | $64.28M+6.8% | ||
| $1.22B+11.7% | $1.09B+17.0% | $935.11M+23.2% | $759.28M+203% | $250.46M+10.8% | ||
| $16.69M+12.5% | $14.84M+9.9% | $13.51M-13.8% | $15.67M+2.6% | $15.27M+14.2% | ||
| -$1.21B-11.7% | -$1.08B-17.1% | -$921.62M-23.5% | -$746.08M-210% | -$240.76M-8.8% | ||
| -$1.59-10.4% | -$1.44-15.2% | -$1.25-22.5% | -$1.02-191% | -$0.35-9.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Summit Therapeutics profitable?
- Summit Therapeutics is not currently profitable: it reported a net loss of $1.2B over the trailing twelve months, a -271685.0% net margin.
- What is Summit Therapeutics's earnings per share?
- Summit Therapeutics's diluted EPS over the trailing twelve months is $-1.59.
- Where does Summit Therapeutics's income statement data come from?
- Every line is extracted from Summit Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.